The research agreement between AstraZeneca and Kiyatec will generate novel preclinical data using Kiyatec's 3D Spheroid Screening Platform, KIYA-Predict™. This partnership could lead to advancements in drug discovery and development, potentially benefiting AstraZeneca's pipeline and future revenues. As a result, the stock price is likely to go up in the short term.